Cargando…

Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial

BACKGROUND: The aim of this study was to compare the antihypertensive efficacy of losartan 100 mg + hydrochlorothiazide (HCTZ) 25 mg versus bisoprolol 10 mg + HCTZ 25 mg and their influence on arterial stiffness and central blood pressure (BP). METHODS: Of 60 patients with a mean BP of 173.3 ± 1.7/9...

Descripción completa

Detalles Bibliográficos
Autores principales: Radchenko, GD, Sirenko, YM, Kushnir, SM, Torbas, OO, Dobrokhod, AS
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3792946/
https://www.ncbi.nlm.nih.gov/pubmed/24109189
http://dx.doi.org/10.2147/VHRM.S44568
_version_ 1782286905346359296
author Radchenko, GD
Sirenko, YM
Kushnir, SM
Torbas, OO
Dobrokhod, AS
author_facet Radchenko, GD
Sirenko, YM
Kushnir, SM
Torbas, OO
Dobrokhod, AS
author_sort Radchenko, GD
collection PubMed
description BACKGROUND: The aim of this study was to compare the antihypertensive efficacy of losartan 100 mg + hydrochlorothiazide (HCTZ) 25 mg versus bisoprolol 10 mg + HCTZ 25 mg and their influence on arterial stiffness and central blood pressure (BP). METHODS: Of 60 patients with a mean BP of 173.3 ± 1.7/98.4 ± 1.2 mmHg, 59 were random-ized to losartan + HCTZ (n = 32) or bisoprolol + HCTZ (n = 27). Amlodipine was added if target BP was not achieved at 1 month, and doxazosin was added if target BP was not achieved after 3 months. Body mass index, office and 24-hour ambulatory BP, pulse wave velocity (carotid-femoral [PWVE] and radial [PWVM]), noninvasive central systolic BP, augmentation index (AIx), laboratory investigations, and electrocardiography were done at baseline and after 6 months of treatment. RESULTS: Losartan + HCTZ was as effective as bisoprolol + HCTZ, with target office BP achieved in 96.9% and 92.6% of patients and target 24-hour BP in 75% and 66.7% of patients, respectively, after 6 months. Effective treatment of BP led to significant lowering of central systolic BP, but this was decreased to a significantly (P < 0.05) greater extent by losartan + HCTZ (−23.0 ± 2.3 mmHg) than by bisoprolol + HCTZ (−15.4 ± 2.9 mmHg) despite equal lowering of brachial BP. Factors correlated with central systolic BP and its lowering differed between the treatment groups. Losartan + HCTZ did not alter arterial stiffness patterns significantly, but bisoprolol + HCTZ significantly increased AIx. We noted differences in ΔPWVE, ΔPWVM, and ΔAIx between the groups in favor of losartan + HCTZ. Decreased heart rate was associated with higher central systolic BP and AIx in the bisoprolol + HCTZ group, but was not associated with increased AIx in the losartan + HCTZ group. CONCLUSION: Although both treatments decreased both office and 24-hour BP, losartan + HCTZ significantly decreased central systolic BP and had a more positive influence on pulse wave velocity, with a less negative effect of decreased heart rate on AIx and central systolic BP.
format Online
Article
Text
id pubmed-3792946
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-37929462013-10-09 Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial Radchenko, GD Sirenko, YM Kushnir, SM Torbas, OO Dobrokhod, AS Vasc Health Risk Manag Original Research BACKGROUND: The aim of this study was to compare the antihypertensive efficacy of losartan 100 mg + hydrochlorothiazide (HCTZ) 25 mg versus bisoprolol 10 mg + HCTZ 25 mg and their influence on arterial stiffness and central blood pressure (BP). METHODS: Of 60 patients with a mean BP of 173.3 ± 1.7/98.4 ± 1.2 mmHg, 59 were random-ized to losartan + HCTZ (n = 32) or bisoprolol + HCTZ (n = 27). Amlodipine was added if target BP was not achieved at 1 month, and doxazosin was added if target BP was not achieved after 3 months. Body mass index, office and 24-hour ambulatory BP, pulse wave velocity (carotid-femoral [PWVE] and radial [PWVM]), noninvasive central systolic BP, augmentation index (AIx), laboratory investigations, and electrocardiography were done at baseline and after 6 months of treatment. RESULTS: Losartan + HCTZ was as effective as bisoprolol + HCTZ, with target office BP achieved in 96.9% and 92.6% of patients and target 24-hour BP in 75% and 66.7% of patients, respectively, after 6 months. Effective treatment of BP led to significant lowering of central systolic BP, but this was decreased to a significantly (P < 0.05) greater extent by losartan + HCTZ (−23.0 ± 2.3 mmHg) than by bisoprolol + HCTZ (−15.4 ± 2.9 mmHg) despite equal lowering of brachial BP. Factors correlated with central systolic BP and its lowering differed between the treatment groups. Losartan + HCTZ did not alter arterial stiffness patterns significantly, but bisoprolol + HCTZ significantly increased AIx. We noted differences in ΔPWVE, ΔPWVM, and ΔAIx between the groups in favor of losartan + HCTZ. Decreased heart rate was associated with higher central systolic BP and AIx in the bisoprolol + HCTZ group, but was not associated with increased AIx in the losartan + HCTZ group. CONCLUSION: Although both treatments decreased both office and 24-hour BP, losartan + HCTZ significantly decreased central systolic BP and had a more positive influence on pulse wave velocity, with a less negative effect of decreased heart rate on AIx and central systolic BP. Dove Medical Press 2013 2013-09-27 /pmc/articles/PMC3792946/ /pubmed/24109189 http://dx.doi.org/10.2147/VHRM.S44568 Text en © 2013 Radchenko et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Radchenko, GD
Sirenko, YM
Kushnir, SM
Torbas, OO
Dobrokhod, AS
Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial
title Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial
title_full Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial
title_fullStr Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial
title_full_unstemmed Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial
title_short Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial
title_sort comparative effectiveness of a fixed-dose combination of losartan + hctz versus bisoprolol + hctz in patients with moderate-to-severe hypertension: results of the 6-month eliza trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3792946/
https://www.ncbi.nlm.nih.gov/pubmed/24109189
http://dx.doi.org/10.2147/VHRM.S44568
work_keys_str_mv AT radchenkogd comparativeeffectivenessofafixeddosecombinationoflosartanhctzversusbisoprololhctzinpatientswithmoderatetoseverehypertensionresultsofthe6monthelizatrial
AT sirenkoym comparativeeffectivenessofafixeddosecombinationoflosartanhctzversusbisoprololhctzinpatientswithmoderatetoseverehypertensionresultsofthe6monthelizatrial
AT kushnirsm comparativeeffectivenessofafixeddosecombinationoflosartanhctzversusbisoprololhctzinpatientswithmoderatetoseverehypertensionresultsofthe6monthelizatrial
AT torbasoo comparativeeffectivenessofafixeddosecombinationoflosartanhctzversusbisoprololhctzinpatientswithmoderatetoseverehypertensionresultsofthe6monthelizatrial
AT dobrokhodas comparativeeffectivenessofafixeddosecombinationoflosartanhctzversusbisoprololhctzinpatientswithmoderatetoseverehypertensionresultsofthe6monthelizatrial